Under a provision of the Inflation Reduction Act, Medicare has begun the historic process of negotiating the prices for a select group of high-cost prescription drugs directly with manufacturers. This report details the first ten drugs chosen for negotiation, which include medications for blood clots, diabetes, and heart failure. This marks the first time Medicare has had the power to negotiate drug prices. The process is expected to lower costs for both the government and seniors, though it is being challenged in court by pharmaceutical companies.
